The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.
06/17/2025 Motion to expedite consideration of the petition for a writ of certiorari before judgment filed by petitioners Learning Resources, Inc., et al. 06/18/2025 Response to motion from ...
October 19, 2025 • NPR's Don Gonyea plays the puzzle with Minnesota Public Radio listener Matt Walsh of St. Louis Park, Minnesota and Weekend Edition Puzzlemaster Will Shortz.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback